Research Institute of the Sant Pau Hospital

Lipids and Cardiovascular Pathology Group (CSIC)

 

Vicenta Llorente-Cortés
David de Gonzalo Calvo

The group of Lipids and Cardiovascular Pathology is interested in the molecular mechanisms associated with the dysregulated lipid accumulation in the vasculature and myocardium, including non-coding RNA. All the research lines have a robust translational perspective, from clinical needs to basic science.        

Expertise

Main research areas

Molecular mechanisms involved in the pathological accumulation of neutral lipids in the cardiovascular system:

  • Molecular mechanisms implicated in the modulation of the receptor LRP1 by cardiovascular risk factors.
  •  Impact of the receptor LRP1 on vascular and myocar¬dial cholesterol accumulation.
  • Impact of lipoproteins on LRP1-iIntracellu¬lar signal pathways under normoxic and hypoxic conditions. 
  • Alterations in LRP1 expression and LRP1-intracellular signal pathways in hy-poxia/ischemia in in vitro and in vivo models.
  • Lipids and diabetic cardiomyopathy.
  • Role of non-coding RNAs in vascular lipid accumulation.
  • Role of non-coding RNAs in myocardial lipid accumulation.

Non-coding RNAs (microRNAs and long-non coding RNAs) as novels diagnostic, prognostic and therapeutic biomarkers of cardiovascular disease:

  • Circulating biomarkers of atherosclerosis.
  • Circulating biomarkers of diabetic cardiomyopathy and diabetes complications. 
  • Circulating biomarkers of dilated cardiomyopathy with special focus on familial dilated cardiomyopathy.
  • Circulating biomarkers for prediction of treatment response.
  • Effect of exercise on the circulating profile of novel biomarkers with potential clinical application.

Lipids and breast cancer.
LRP1 and inflammation.

Summary of methods available for cooperation

  • Non-coding based techniques: microRNA and lncRNA profiling in cells, tissues and body fluids (plasma and serum) by real-time PCR (RT-qPCR). 
  • In vitro models:
    • Primary culture of human coronary and aortic smooth muscle cells
    • HL-1 cardiomyocytes.
  • In vivo model: transgenic mice with tissue-specific LRP1 modulation to proceed to in-depth analysis of LRP1-dependent mechanisms. 
  • Extracellular vesicles: microvesicle isolation and characterization (flow cytometry, immunoblot, RNA profile).
  • Lipids:
    • lipoprotein isolation and modification
    • determination of neutral lipid content in cells and tissues
    • lipoprotein internalization.
  • Molecular Biology:
    • Molecular cloning
    • Cellular transfection
    • Promoter activity
    • Real-time PCR
    • Western blot analysis
    • Immunoprecipitation

Interested in collaborating on

  • Establish collaborations with Cardiolinc members with the final aim of increasing our expertise in other molecular biology techniques such as global transcriptomic analysis or functional analysis and other in vitro and in vivo models.
  • Establish collaborations with Cardiolinc members with the final aim of developing new products useful in diagnosis, prognosis or therapy.
  • Establish international collaborations to set up future applications for European funding.

Selected publications on lncRNA

Circulating Long Noncoding RNAs in Personalized Medicine: Response to Pioglitazone Therapy in Type 2 Diabetes
de Gonzalo-Calvo D, Kenneweg F, Bang C, Toro R, van der Meer RW, Rijzewijk LJ, Smit JW, Lamb HJ, Llorente-Cortes VThum TJ Am Coll Cardiol. 68(25):2914-2916.

Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes
de Gonzalo-Calvo D, Kenneweg F, Bang C, Toro R, van der Meer RW, Rijzewijk LJ, Smit JW, Lamb HJ, Llorente-Cortes VThum TSci Rep. 2016, 6:37354.

Website
cllorente@csic-iccc.org
david.degonzalo@gmail.com

Sant Antoni Maria Claret, 167
08025 Barcelona
Spain